AR113224A1 - Conjugados de anticuerpo que comprenden un agonista de sting - Google Patents

Conjugados de anticuerpo que comprenden un agonista de sting

Info

Publication number
AR113224A1
AR113224A1 ARP180101063A ARP180101063A AR113224A1 AR 113224 A1 AR113224 A1 AR 113224A1 AR P180101063 A ARP180101063 A AR P180101063A AR P180101063 A ARP180101063 A AR P180101063A AR 113224 A1 AR113224 A1 AR 113224A1
Authority
AR
Argentina
Prior art keywords
antibody conjugates
sting agonist
conjugates including
immunoconjugates
methods
Prior art date
Application number
ARP180101063A
Other languages
English (en)
Spanish (es)
Inventor
Yongqin Wan
Tom Yao Wu
- Uno Tetsuo Hsiang
George Scott Tria
Leonard Sung
Weijia Ou
Chudiobioma Ndubaku
Sarah Mwhirter
Jeffrey Mkenna
Justin Leong
Thanh Ngoc Lan Le
George Edwin Katibah
Shailaja Kasibhatla
David Kanne
Xueshi Hao
Laura Glickman
Kelsey Gauthier
Thomas W Dubensky
Charles Y Cho
Stephen Canham
Jacob Robert Bruml
Original Assignee
Novartis Ag
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Aduro Biotech Inc filed Critical Novartis Ag
Publication of AR113224A1 publication Critical patent/AR113224A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP180101063A 2017-04-28 2018-04-25 Conjugados de anticuerpo que comprenden un agonista de sting AR113224A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762491879P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
AR113224A1 true AR113224A1 (es) 2020-02-19

Family

ID=62165655

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101063A AR113224A1 (es) 2017-04-28 2018-04-25 Conjugados de anticuerpo que comprenden un agonista de sting

Country Status (5)

Country Link
EP (1) EP3615080A1 (ja)
JP (1) JP2020517700A (ja)
CN (1) CN110799218A (ja)
AR (1) AR113224A1 (ja)
WO (1) WO2018200812A1 (ja)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3380126A4 (en) 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
AU2018364708A1 (en) 2017-11-10 2020-05-21 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
CA3099680A1 (en) 2018-05-09 2019-11-14 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
AU2019277679A1 (en) * 2018-06-01 2020-12-24 Eisai R&D Management Co., Ltd. Methods for the treatment of bladder cancer
EP3820477A4 (en) * 2018-07-10 2022-07-13 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
WO2020089815A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
EP3873938A1 (en) * 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody conjugates comprising sting agonists
JOP20210159A1 (ar) * 2018-12-21 2023-01-30 Novartis Ag أجسام مضادة لـ pmel17 ومترافقات منها
MA55805A (fr) * 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP2022531899A (ja) 2019-05-09 2022-07-12 アリゴス セラピューティクス インコーポレイテッド Stingモジュレータとしての修飾環状ジヌクレオシド化合物
MX2021013657A (es) * 2019-05-10 2022-02-21 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
TW202100184A (zh) 2019-05-20 2021-01-01 瑞士商諾華公司 Mcl-1抑制劑抗體-藥物結合物及使用方法
BR112022000854A2 (pt) 2019-07-19 2022-03-08 Immunesensor Therapeutics Inc Conjugados anticorpo - agonista de sting e seu uso em imunoterapia
BR112022001931A2 (pt) 2019-08-02 2022-06-21 Mersana Therapeutics Inc Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer
MX2022002152A (es) * 2019-08-21 2022-05-18 Scripps Research Inst Agonistas biciclicos del estimulador de genes de interferon sting.
KR20210028544A (ko) * 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2021046426A1 (en) * 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies
US20230074385A1 (en) * 2019-12-23 2023-03-09 Eisai R&D Management Co., Ltd. Method for producing eribulin-based antibody-drug conjugate
CA3168368A1 (en) * 2020-03-06 2021-09-10 Masayuki Ishizaki Antibody-drug conjugate including novel cyclic dinucleotide derivative
EP4218826A3 (en) * 2020-04-02 2023-10-25 Mersana Therapeutics, Inc. Antibody drug conjugates comprising sting agonists
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
CN115803032A (zh) 2020-05-15 2023-03-14 免疫传感器治疗股份有限公司 Sting激动剂与免疫检查点抑制剂的联合治疗
CN111592570B (zh) * 2020-05-15 2022-04-29 清华大学 新型sting激动剂及其制备方法和应用
AU2021374958A1 (en) 2020-11-09 2023-06-22 Takeda Pharmaceutical Company Limited Antibody drug conjugates
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
WO2022223619A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy
EP4326768A1 (en) 2021-04-23 2024-02-28 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
JP2024526874A (ja) 2021-07-23 2024-07-19 イミューンセンサー セラピューティクス、インコーポレイテッド サイトカインとのstingアゴニスト併用療法
CN118524854A (zh) * 2021-12-17 2024-08-20 北京加科思新药研发有限公司 包含可用作sting激动剂的新型化合物的化合物-连接基构建体及其用途
US20240218011A1 (en) 2022-07-21 2024-07-04 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024100449A1 (en) * 2022-11-08 2024-05-16 Legochem Biosciences, Inc. Sting agonists
WO2024153127A1 (zh) * 2023-01-18 2024-07-25 泰励生物科技(上海)有限公司 抗体偶联药物及其用途
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
LT2281006T (lt) 2008-04-30 2017-11-27 Immunogen, Inc. Skersinių jungčių linkeriai ir jų panaudojimas
IN2015DN02913A (ja) 2012-11-30 2015-09-18 Novartis Ag
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
MX2015010146A (es) 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
EP2991655B1 (en) 2013-04-29 2024-04-10 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
EP3653637A1 (en) * 2013-05-18 2020-05-20 Aduro BioTech, Inc. Compositions and methods for activating "stimulator of interferon genes"-dependent signalling
EP3071229A4 (en) 2013-11-22 2017-05-10 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
JP6462006B2 (ja) 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingのモジュレーターとしての環式ジヌクレオチド
CN107148424B (zh) 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
WO2016145102A1 (en) * 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US20180117171A1 (en) * 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2017004499A1 (en) 2015-07-02 2017-01-05 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
WO2017011622A1 (en) 2015-07-14 2017-01-19 Spring Bank Pharmaceuticals, Inc. Compounds and compositions that induce rig-i-and other pattern recongnition receptors
JP6878405B2 (ja) * 2015-07-29 2021-05-26 ノバルティス アーゲー Pd−1に対する抗体分子を含む組み合わせ治療
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
EP3386536A4 (en) * 2015-12-07 2019-07-31 Opi Vi- IP Holdco LLC COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF
CN106540256A (zh) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
WO2018009652A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
AU2017293781B2 (en) 2016-07-06 2022-12-22 Invox Pharma Limited Compounds, compositions, and methods for the treatment of disease
JP2019521138A (ja) 2016-07-15 2019-07-25 スペロビー・バイオサイエンシズ・インコーポレイテッド 疾患の治療のための化合物、組成物、および方法
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease

Also Published As

Publication number Publication date
JP2020517700A (ja) 2020-06-18
EP3615080A1 (en) 2020-03-04
WO2018200812A1 (en) 2018-11-01
CN110799218A (zh) 2020-02-14

Similar Documents

Publication Publication Date Title
AR113224A1 (es) Conjugados de anticuerpo que comprenden un agonista de sting
ECSP18038868A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
CL2018003406A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CL2019003050A1 (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinación.
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CO2017010618A2 (es) Anticuerpos contra icos
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
CY1124230T1 (el) Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
UY38433A (es) Conjugados de anticuerpo dc–sign que comprenden agonistas de sting
BR112017026027A2 (pt) combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
CL2018002050A1 (es) Conjugados anticuerpo-fármaco dirigidos a gcc.
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso
CO2020008886A2 (es) Métodos para el procesamiento de materias primas de hidrocarburos

Legal Events

Date Code Title Description
FB Suspension of granting procedure